Using eye scans to detect early signs of Alzheimer's disease
Validation of Lens Beta-Amyloid as a Novel Biomarker for Early Detection of Alzheimer's Disease at the Boston University Alzheimer's Disease Research
This study is testing a new eye scanner that can safely and easily check for early signs of Alzheimer's disease by looking for a specific marker in your eye, helping to catch the condition before symptoms start and allowing for earlier treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10934601 on NIH RePORTER |
What this research studies
This research focuses on developing a non-invasive eye scanner that can detect beta-amyloid, a key biomarker for Alzheimer's disease, in the lens of the eye. By identifying this biomarker early, before cognitive symptoms appear, the research aims to facilitate timely intervention and treatment. The approach utilizes a novel device that has received FDA Breakthrough Device designation, making it a promising alternative to current invasive and expensive methods like PET scans and cerebrospinal fluid analysis. Patients will be assessed for the presence of Alzheimer's-related pathology through this innovative technology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's disease, particularly those with genetic predispositions such as the APOE-ε4 allele.
Not a fit: Patients who are already diagnosed with advanced Alzheimer's disease or those without any risk factors for the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accessible detection of Alzheimer's disease, allowing for timely treatment and better management of the condition.
How similar studies have performed: Other research has shown promise in using biomarkers for early detection of Alzheimer's, but this specific approach using eye scans is relatively novel.
Where this research is happening
Boston, United States
- Boston University Medical Campus — Boston, United States (Active)
Researchers
- Principal investigator: Goldstein, Lee E. — Boston University Medical Campus
- Study coordinator: Goldstein, Lee E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.